Reata Announces Promotion and New Hires For Key Leadership Roles
July 07 2020 - 6:45AM
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,”
or “we”), a clinical-stage biopharmaceutical company, today
announced the expansion of its leadership team and the appointment
of several experienced industry leaders to key management
roles.
Colin J. Meyer, MD has been promoted to the
newly created position of Chief Research and Development Officer
and Executive Vice President. In this role, Dr. Meyer will be
responsible for the strategic direction of the Company’s research,
development, and clinical functions, with a focus on advancing the
development of Reata’s robust product pipeline. Dr. Meyer
will lead the Company’s efforts to explore additional indications
for bardoxolone methyl (“bardoxolone”) and omaveloxolone and to
advance the Phase 2-ready molecules RTA 901 and RTA 1701. Dr.
Meyer joined Reata in 2003. He was involved with the initial
in-licensing activities that resulted in the acquisition of several
of Reata’s technologies, including its Nrf2 activators. Dr.
Meyer held various roles of increasing responsibility in Clinical,
Regulatory, and Product Development before being appointed to the
role of Chief Medical Officer in 2013.
In addition, Reata welcomes the following new hires—all of whom
have significant industry and commercial experience—to key
leadership positions within the Company:
- Seemi Khan, MD has been named Chief Medical Officer at
Reata. Dr. Khan, a U.S. trained internist and nephrologist,
will have responsibility for all clinical development programs,
from late preclinical to pivotal Phase 3 trials, as well as
completion of post-approval commitments and medical affairs
activities across the Company’s therapeutic areas. Dr. Khan
served as a nephrology faculty member at Tufts University,
Boston. Her prior industry experience includes leadership
roles at Mitsubishi Tanabe, Quark Pharma, and AbbVie.
- Andrea Loewen has joined Reata as Vice President, Global
Regulatory Affairs. Her career in the biopharmaceutical
industry spans more than 30 years at Shire, Biogen, Baxter
Healthcare, and a number of smaller biopharmaceutical companies.
She has significant leadership experience developing and
implementing innovative regulatory strategies, building out global
regulatory organizations and capabilities, engaging and
negotiating with health authorities, and preparing and filing
development and registration dossiers, including New Drug
Applications (NDAs), Biologics License Applications, and EU
Marketing Authorisation Applications (MAAs).
- Kevin Johnston joins Reata as Vice President and Chief
Technical Officer. In this role, Mr. Johnston will be
responsible for establishing and leading the Company’s
manufacturing and supply chain organization. Mr. Johnston has
over 20 years of global pharmaceutical management and leadership
experience in small-molecule development and manufacturing.
Most recently, he served as Vice President of Supply Chain
& Logistics at TESARO, Inc., where he built and led a
late-stage clinical and commercial manufacturing and supply chain
organization that enabled multiple, small-molecule NDA and MAA
approvals and launches, in addition to supporting global clinical
supply management.
"We are delighted to make these key additions to our leadership
team," said Warren Huff, Reata’s Chief Executive Officer and
President. “Each of these individuals brings a critical set
of skills to the organization as we transition from a late-stage
research and development company to a multi-product,
commercial-stage company with a robust and sustainable pipeline of
innovative medicines.”
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical
company that develops novel therapeutics for patients with serious
or life-threatening diseases by targeting molecular pathways
involved in the regulation of cellular metabolism and inflammation.
Reata’s two most advanced clinical candidates, bardoxolone
and omaveloxolone, target the important transcription factor Nrf2
that promotes the resolution of inflammation by restoring
mitochondrial function, reducing oxidative stress, and inhibiting
pro-inflammatory signaling. Bardoxolone and
omaveloxolone are investigational drugs, and their safety and
efficacy have not been established by any agency.
Contact:Reata Pharmaceuticals, Inc.(972)
865-2219http://reatapharma.com
Investors:Vinny JindalVice President, Corporate
Communications and Strategy(469)
374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” including, without
limitation, statements regarding the success, cost and timing of
our product development activities and clinical trials, our plans
to research, develop and commercialize our product candidates, our
plans to submit regulatory filings, and our ability to obtain and
retain regulatory approval of our product candidates. You can
identify forward-looking statements because they contain words such
as “believes,” “will,” “may,” “aims,” “plans,” “model,” and
“expects.” Forward-looking statements are based on Reata’s
current expectations and assumptions. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks, and changes in circumstances that may differ
materially from those contemplated by the forward-looking
statements, which are neither statements of historical fact nor
guarantees or assurances of future performance. Important
factors that could cause actual results to differ materially from
those in the forward-looking statements include, but are not
limited to, (i) the timing, costs, conduct, and outcome of our
clinical trials and future preclinical studies and clinical trials,
including the timing of the initiation and availability of data
from such trials; (ii) the timing and likelihood of regulatory
filings and approvals for our product candidates; (iii) whether
regulatory authorities determine that additional trials or data are
necessary in order to obtain approval; (iv) the potential market
size and the size of the patient populations for our product
candidates, if approved for commercial use, and the market
opportunities for our product candidates; and (v) other factors set
forth in Reata’s filings with the U.S. Securities and Exchange
Commission, including the detailed factors discussed under the
caption “Risk Factors” in its Annual Report on Form 10-K for the
fiscal year ended December 31, 2019. The forward-looking
statements speak only as of the date made and, other than as
required by law, we undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Apr 2023 to Apr 2024